SCHEMBL2318318

SCHEMBL2318318

CC(C)(NC(=O)Nc1ccc(OC(F)(F)F)cc1)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.46
RORC P51449 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.43
PLTP P55058 3/20 0.42
DGAT1 O75907 2/20 0.42
MAPT P10636 1/20 0.42
IGF1R P08069 2/20 0.42
EPHX2 P34913 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
P2RY1 P47900 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2316339 0.89 RORC (0.47) FPR2RORCPTGDR2PLTPDGAT1
SCHEMBL2487641 0.89 DGAT1 (0.49) RORCPLTPDGAT1MAPTKMT2A
SCHEMBL2317569 0.84 AR (0.52) RORCPLTPDGAT1MAPTALDH1A1
SCHEMBL2317084 0.83 MAPT (0.45) RORCPLTPDGAT1MAPTMEN1
SCHEMBL2315078 0.83 DHODH (0.49) RORCPLTPMAPTKMT2AGAA
SCHEMBL2316628 0.81 RORC (0.48) RORCPLTPDGAT1MAPTMEN1
SCHEMBL2316421 0.80 GAA (0.53) RORCPTGDR2PLTPDGAT1MAPT
SCHEMBL2360023 0.80 TRPV1 (0.49) RORCPLTPDGAT1MAPTMEN1
SCHEMBL2319840 0.80 PLTP (0.48) RORCPLTPDGAT1MAPTKMT2A
SCHEMBL2312708 0.80 TP53 (0.50) RORCPTGDR2PLTPDGAT1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2349484-A2 HETEROARYL DERIVATIVES AS DGAT1 INHIBITORS Novartis AG (CH) 2011-08-03 EP disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed
WO-2010007046-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 FPR2 3065/4885RORC 1166/4885PTGDR2 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.